Key result
D-PLT co-loaded with urokinase and atorvastatin improved rapid vascular opening of arterial and venous thrombosis in 90 min and provided up to 7 days of durable thrombolysis in vivo.
Why the study?
Heterogeneity of thrombi regarding composition, structure, and blood rheology parameters poses a challenge for effective thrombus-targeting drug delivery.
Does a self-adaptive nano-delivery system co-loaded with urokinase and atorvastatin improve thrombolysis and endothelial repair in in vivo models of thrombosis?
Does a self-adaptive nano-delivery system co-loaded with urokinase and atorvastatin improve thrombolysis and endothelial repair in in vivo models of thrombosis?
A novel platelet membrane-cloaked deformable nanocomposite co-loaded with urokinase and atorvastatin provides rapid and durable targeted thrombolysis and endothelial repair in vivo.
Advances preclinical adaptive nanodelivery for heterogeneous thrombi; leaves open clinical translation and efficacy testing.
The heterogeneity of thrombi in terms of composition, structure, and blood rheology parameters presents a challenge for effective thrombus-targeting drug delivery. To address this, a self-adaptive nano-delivery system, termed D-PLT, is developed. It consists of platelet membrane-cloaked deformable mesoporous organic silicon dioxide nanocomposite, enabling it to respond to the challenge of the heterogeneity of thrombi in arteries and veins. The system exhibits progressive targeting, with the ability to target arterial and venous thrombosis and damaged blood vessels. D-PLT physically matches the pore structure of the thrombus by undergoing varied deformation, leading to advanced targeting and enrichment of arterial and venous thrombus. When co-loaded with the thrombolytic drug urokinase (UK) and the endothelium-protecting agent atorvastatin calcium (AT), the system improves rapid vascular opening of arterial and venous thrombosis in 90 min and provides up to 7 days of durable thrombolysis and recovery from endothelial dysfunction in vivo. This self-adaptive delivery system offers a promising strategy to overcome thrombus heterogeneity.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) studied Arterial and venous thrombosis. D-PLT co-loaded with urokinase (UK) and atorvastatin calcium (AT) was evaluated on Vascular opening, thrombolysis, and recovery from endothelial dysfunction. D-PLT co-loaded with urokinase and atorvastatin improved rapid vascular opening of arterial and venous thrombosis in 90 min and provided up to 7 days of durable thrombolysis in vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: